This site is intended for health professionals only
Wednesday 23 January 2019
Share |

Topic: *** Editor's Pick

January 17, 2019
Erleada™ (apalutamide) offers a new treatment option for men with non-metastatic castration-resistant prostate cancer who are at high risk of metastatic disease
Janssen has announced that the European Commission (EC) has licensed Erleada (apalutamide), for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.
 
Prostate cancer is the most common cancer in men in the UK,1 resulting in over 47,000 diagnoses each year, or 129 each day.2
 
January 16, 2019
A university has been given more than £2m to conduct research into opiod overprescribing in the NHS.

A university has been given more than £2m to conduct research into opiod overprescribing in the NHS.
 

January 15, 2019
Former regional pharmaceutical officer for the Israeli Ministry of Health Yaakov Cass outlines his views on how hospital pharmacists should handle hazardous drugs

Former regional pharmaceutical officer for the Israeli Ministry of Health Yaakov Cass outlines his views on how hospital pharmacists should handle hazardous drugs
 
Can you tell our readers a bit about yourself?
 

January 14, 2019
Three people have been imprisoned for their part in illegally supplying prescription-only medicines, the Government’s medicines watchdog has reported.

Three people have been imprisoned for their part in illegally supplying prescription-only medicines, the Government’s medicines watchdog has reported.
 

January 11, 2019
Commonly prescribed drugs for diabetes, heart conditions and high blood pressure could help treat severe mental health problems, a study has shown.

Commonly prescribed drugs for diabetes, heart conditions and high blood pressure could help treat severe mental health problems, a study has shown.
 

January 10, 2019
Ensuring extra refrigerated storage to stockpile temperature-sensitive medicines in the case of a no-deal Brexit will cost £1m, the Government has revealed.

Ensuring extra refrigerated storage to stockpile temperature-sensitive medicines in the case of a no-deal Brexit will cost the UK £1m, the Government has revealed.

January 9, 2019
Hospital pharmacists deserve more recognition than they got from this major planning document

If you’re a pharmacist working in the UK, you may have seen a lot in the news about the NHS Long Term Plan, a major planning document setting out NHS England’s priorities for health over the next decade.
 
On the one hand, it is heartening to see several mentions of pharmacy peppered throughout the document (26 at last count) given that pharmacists so often seem to go unnoticed by the great and the good.
 

January 8, 2019
The change follows concerns around fatalities resulting from the misuse of the medicines

Pregabalin and gabapentin will be reclassified as Class C controlled drugs from 1 April, 2019.
 
The change means doctors will have to physically sign prescriptions for the drugs, rather than sending electronic copies, and pharmacists must dispense within 28 days of the prescription being written.
 
The drugs, which can be used to treat anxiety, nerve pain and epilepsy, will be included in the ‘exempted drugs’ list, which means they do not need to be stored in a controlled drugs cabinet.
 

January 7, 2019
New plans for the NHS to tackle ‘killer conditions’ such as strokes and heart attacks could save up to half a million lives, the UK’s Government has announced.

The NHS Long Term Plan, published today (7 January) outlines how over three million people will be treated from new stroke, respiratory and cardiac services over the next decade.
 
The measures, supported by £4.5bn in new service model funding, will help prevent over 150,000 heart attacks, strokes and cases of dementia, according to the plan.
 
Measures in the plan will also help over three million people through improved stroke, respiratory and cardiac services over the next 10 years, it said.
 

January 4, 2019
The medicines watchdog has recalled certain batches of products containing ibesartan made by the manufacturer Accord (formerly Actavis) over contamination fears.

The medicines watchdog has recalled certain batches of products containing ibesartan made by the manufacturer Accord (formerly Actavis) over contamination fears.
 
The Medicines and Healthcare products Regulatory Agency (MHRA) yesterday (3 January) recalled the products as a 'precautionary measure' following possible N‑nitrosodiethylamine (NDEA) contamination.
 
It comes as part of a wider European investgation into sartan products, it said.
 

January 3, 2019
What the Department of Health and Social Care’s ‘operational readiness’ guidance says about exiting the EU

There is now a draft basis on which the UK is due to leave the European Union (EU) in March 2019 – but in the event of a ‘no deal’ exit, officials want the health and care system to be prepared.
 
Enter the EU Exit Operational Readiness Guidance – a 34-page document from the Department of Health and Social Care (DHSC) summarising the contingency plans.
 

December 12, 2018
The Government has chosen England’s chief pharmacist to look into ‘problematic’ overprescribing in the NHS, it has announced.

The Government has chosen England’s chief pharmacist to look into "problematic" overprescribing in the NHS, it has announced.
 

December 11, 2018
A no-deal Brexit could create disruption over importing and exporting medicines at the Anglo-French border for up to six months, the Government has predicted.

A no-deal Brexit could create disruption over importing and exporting medicines at the Anglo-French border for up to six months, the Government has predicted.
 
In a letter published on 7 December, health and social care secretary Matt Hancock said Britain exiting the European Union without a deal will "significantly" reduce access across the channel for "up to six months".
 

December 6, 2018
Delays in taking new cancer drugs through clinical trials and getting them approved for use mean NHS patients are waiting longer to access them, a report by the Institute of Cancer Research (ICR) finds.

NHS patients are waiting longer for new cancer drugs because of delays in taking them through clinical trials and getting them approved for use, a new report has revealed.
The average time from when a cancer drug is patented to approval by NICE increased from 12.7 years between 2000-08 to 14.1 years between 2009-16, The Institute of Cancer Research, London (ICR) found.

December 6, 2018
Research shows 31% of medication administration errors in English and Welsh acute care trusts are due to omitted medicine or ingredient.

Three in 10 drug-related deaths occurring in acute care settings are caused by omission, a study has revealed.
 

December 6, 2018
Leading academics and health data specialists have formed an alliance to boost science and innovation in the UK

The UK’s leading academics and health data specialists have formed an alliance to develop new ways to design and support the medical research of the future, and to improve the care patients receive from the NHS.
 
The UK Health Data Research Alliance will look atthe best ways to design, use, collect, manage and analyse health data in a responsible way for clinical trials, medical research, and innovation.
 

November 29, 2018
First child cancer patients treated with new CAR-T therapy in UK

Children with cancer at Great Ormond Street Hospital in London are this week starting a new therapy treatment tailored to target patients’ specific cancer cells.
 
The CAR-T treatment involves collecting and using a patient’s own immune cells to fight the cancer over a number of weeks. 
 
Royal Manchester Children’s Hospital is also offering the immunotherapy treatment, and Newcastle upon Tyne Hospitals NHS Foundation Trust will join next month.
 

November 29, 2018
In the EU, regorafenib is indicated for treatment of adult patients with advanced unresectable hepatocellular carcinoma who have been previously treated with sorafenib
Bayer has announced that the National Institute for Health and Care Excellence (NICE) has recommended Stivarga® (regorafenib) as an option for treating advanced unresectable hepatocellular carcinoma (HCC) in adults who have had Nexavar® (sorafenib) only if patientshave Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.1
 
November 29, 2018
A survey of people working within pharmaceutical industry within and outside the UK found growing negativity about the impact of Brexit on the UK healthcare sector

The majority of pharmaceutical professionals now say Brexit will have a negative impact on the UK healthcare sector, a survey has revealed.
 
Negative sentiment amongst healthcare professionals about the impact of Brexit on the UK healthcare sector has increased over the last three months, according to data and analytics company GlobalData.

November 28, 2018
Data from the ALTA trial showed sustained systemic and intracranial efficacy results and a manageable safety profile, leading to the longest progression-free survival and overall survival reported in this setting

Takeda has announced that the European Commission (EC) granted marketing authorisation for Alunbrig (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.

 

The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on 20 September, 2018. 

 

November 27, 2018
NHS on track to make £300m in savings after adalimumab deals

The NHS is on track to make record savings of £300m after negotiating deals on low cost versions of the health service’s most expensive drug.

 

Deals with five manufacturers have been made to on biosimilar versions of adalimumab. The drug is used to treat 46,000 patients with conditions including rheumatoid arthritis, inflammatory bowel disease and psoriasis.

 

The savings will mean hospitals will pay around a quarter of the amount they usually spend on adalimumab, which is over £400m each year.

 

November 22, 2018
The amount of money medicines cost the NHS has more than doubled in less than 10 years, official figures have revealed

The amount of money medicines cost the NHS has more than doubled in less than 10 years, official figures have revealed.
 

November 22, 2018
AR101 slowly builds up tolerance to peanut allergy, study finds

A new oral biologic drug could reduce the risk of allergic reaction in children and adolescents following accidental peanut exposures, research has shown.
 

November 20, 2018
Galcanezumab is a humanised monoclonal antibody that binds to the calcitonin gene-related peptide, which plays a role in migraine attacks, blocking its downstream function

Eli Lilly and Company has announced that the European Commission (EC) has granted marketing authorisation for Emgality® (galcanezumab) for the prophylaxis of migraine in adults who have at least four migraine days per month.1

 

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine